

**Table 3**

Mean ADCs in the enhancing lesion, contralateral hemisphere, T2 prolongation, and results of normalization

		<b>ADC mean</b>		<b>ADC ratio E</b>	<b>ADC diff E</b>	<b>ADC ratio T2</b>	<b>ADC diff T2</b>	<b>ADC ratio E/T2</b>
	<b>E</b>	<b>contralateral</b>	<b>T2</b>	<b>RECURRANCE GROUP</b>				
# 1	1.18	0.83	1.45	1.42	0.35	1.75	0.62	0.81
# 2	1.48	0.95	1.56	1.56	0.53	1.64	0.62	0.95
# 3	1.05	0.82	1.84	1.28	0.23	2.24	1.02	0.57
# 4	1.24	0.84	1.38	1.48	0.40	1.64	0.58	0.9
# 5	1.14	0.85	1.51	1.34	0.21	1.72	0.63	0.75
# 6	1.12	0.75	1.67	1.50	0.37	2.23	0.92	0.67
# 7	1.17	0.69	1.39	1.47	0.48	2.01	0.70	0.84
# 8	1.13	0.84	1.64	1.35	0.29	1.95	0.80	0.69
# 9	1.28	0.85	1.46	1.51	0.43	1.72	0.61	0.88
# 10	1.10	0.85	1.35	1.29	0.25	1.59	0.50	0.81
# 11	0.96	0.71	1.47	1.35	0.25	2.07	0.76	0.65
# 12	1.26	0.78	1.51	1.62	0.48	1.94	0.73	0.83
<b>mean</b>	<b>1.18</b>	<b>0.81</b>	<b>1.52</b>	<b>1.43</b>	<b>0.36</b>	<b>1.88</b>	<b>0.71</b>	<b>0.78</b>
<b>SD</b>	<b>0.13</b>	<b>0.07</b>	<b>0.14</b>	<b>0.11</b>	<b>0.11</b>	<b>0.23</b>	<b>0.15</b>	<b>0.11</b>
				<b>NON-RECURRENCE GROUP</b>				
# 13	1.52	0.85	1.71	1.79	0.67	2.01	0.86	0.89
# 14	1.38	0.74	0.98	1.85	0.64	1.32	0.24	1.18
# 15	1.55	0.85	1.69	1.82	0.70	1.99	0.84	0.92
# 16	1.33	0.71	0.91	1.87	0.62	1.28	0.20	1.46
# 17	1.51	0.80	0.93	1.88	0.71	1.16	0.13	1.62
# 18	1.11	0.66	1.27	1.68	0.45	1.92	0.61	0.87
<b>mean</b>	<b>1.40</b>	<b>0.77</b>	<b>1.25</b>	<b>1.82</b>	<b>0.63</b>	<b>1.61</b>	<b>0.46</b>	<b>1.16</b>
<b>SD</b>	<b>0.17</b>	<b>0.08</b>	<b>0.37</b>	<b>0.07</b>	<b>0.10</b>	<b>0.40</b>	<b>0.35</b>	<b>0.32</b>

E = enhancing lesion; T2 = area of T2 prolongation

ADC ratio <sub>E</sub> = ratio enhancing lesion / contralateral hemisphere; ADC diff <sub>E</sub> = difference between enhancing lesion and contralateral hemisphere

ADC ratio <sub>T2</sub> = ratio T2 prolongation / contralateral hemisphere; ADC diff <sub>T2</sub> = difference between T2 prolongation and contralateral hemisphere

ADC ratio <sub>E/T2</sub> = ratio enhancing lesion / T2 prolongation